[1] Osei-Hyiaman D,Liu J,Zhou L,et al. Hepatic CB1 receptor is required for development of diet-induced steatosis,dyslipidemia,and insulin and leptin resistance in mice. J Clin Invest,2008,118（9）:3160-3169.
[2] Jourdan T,Demizieux L,Gresti J,et al. Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice:evidence from cultured explants. Hepatology,2012,55（3）:790-799.
[3] Andrews DB,Schwimmer JB,Lavine JE. Fast break on the fat brake:mechanism of peroxisome proliferator-activated receptor-delta regulation of lipid accumulation in hepatocytes. Hepatology,2008,48（2）:355-357.
[4] Cariou B,Zar Y,Staels B,et al. Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care,2011,34（9）:2008-2014.
[5] Zhang S,Wang J,Liu Q,et al. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol,2009,51（2）:380-388.
[6] Walsh MJ,Vanags DM,Clouston AD,et al. Steatosis and liver cell apoptosis in chronic hepatitis C:a mechanism for increased liver injury. Hepatology,2004,39（5）:1230-1238.
[7] Anstee QM,Concas D,Kudo H,et al. Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J Hepatol,2010,53（3）:542-550.
[8] Witek RP,Stone WC,Karaca FG,et al. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology,2009,50（5）:1421-1430.
[9] Ratziu V,Sheikh MY,Sanyal AJ,et al. A phase 2,randomized, double-blind,placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology,2012,55（2）:419-428. |
